Monogram is proud to apply our expertise in virology and drug resistance testing to the hepatitis C virus (HCV). We are actively developing a new portfolio of products to assist with drug development and the treatment of patients infected with HCV. We also offer an extensive line of diagnostic tests to aid in patient management in addition to our HCV drug resistance assays. In July 2011, Monogram launched HCV GenoSure® NS3/4A, the industry’s first drug resistance assay for HCV and direct acting antivirals (DAAs).
Diagnostic Testing Offered at Monogram:
- Hepatitis C Virus Genotyping (subtype)
- Interleukin 28B (IL28B) Polymorphism
- HCV GenoSure NS3/4A Drug Resistance Assay
Hepatitis C Testing for Pharma
Pharmaceutical companies are using our HCV resistance assays to support all phases of research and clinical development for several new HCV compounds. Our phenotypic and genotypic sequencing assays offered to pharmaceutical companies target all the major steps in the HCV replication cycle, including the NS3 protease, NS5A, and the NS5B polymerase. As more compounds reach the clinic, our assays will continue to provide useful information for the incorporation of DAAs into patient management.
For more information about Monogram’s full line of HIV, HCV, or pharmaceutical services, visit our Pharma Collaborations page.